遠大醫藥(00512.HK)：治療乾眼症的全球首創鼻噴產品OC-01正式獲批後在中國大陸實現首批商業化處方落地
格隆匯7月17日丨遠大醫藥(00512.HK)公告，近日，集團全球首創用於增加乾眼症患者淚液分泌的鼻噴產品酒石酸伐尼克蘭鼻噴霧劑(OC-01)，在正式獲批後於中山大學附屬第一醫院和深圳市眼科醫院實現中國大陸首批商業化處方落地。這一里程碑進展標誌着中國乾眼症治療迎來全新選擇：中國目前唯一一款獲批上市的用於增加乾眼症患者淚液分泌的鼻噴產品正式投入臨牀應用，爲中國乾眼症患者提供一種全新的治療方案。
OC-01 是高選擇性的煙礆乙酰膽礆受體激動劑，普遍認爲可通過啓動三叉神經副交感神經通路，增加基礎淚液的分泌，從而增加乾眼症患者的淚液分泌。該產品於2021年10月在美國獲批上市，是目前全球首款且唯一一款獲批治療患者乾眼症症狀的鼻噴霧劑；中國大陸方面，該產品於2024年11月獲得中國國家藥品監督管理局批準上市；此外，OC-01 於2023年2月在中國澳門特別行政區獲批上市；於2023年4月作爲進口臨牀急需藥品，落地海南樂城醫療先行區；於2024年11月在中國臺灣地區獲批上市。
集團始終以眼科領域作爲重要戰略發展方向之一，持續聚焦眼科藥物創新，堅持專業化發展道路，不斷提升行業地位和市場競爭力。目前，集團已構建了「專業化、全系列、多品種」的創新藥物產品體系，儲備了治療「近視」、「乾眼症」、「翼狀胬肉」、「眼科術後抗炎鎮痛」、「蠕形蟎瞼緣炎」和「蠕形蟎導致的瞼板腺功能障礙」的多款全球創新產品，且取得了重大研發進展，未來三年將有多款創新產品有望獲批上市。
集團一直高度重視創新產品和先進技術的研發，以患者需求爲核心，以科技創新爲驅動，針對尚未滿足的臨牀需求，加大對全球創新產品和先進技術的投入，豐富和完善產品管線及產業佈局，採用「全球化運營佈局，雙循環經營發展」策略，形成國內國際雙循環聯動發展並相互促進的新格局，充分發揮集團的產業優勢和研發實力，快速將科技創新產品落地上市，爲全球患者提供更先進更多樣的治療方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
